Atlas Venture Life Science Advisors, LLC

CIK 0001917529 · CAMBRIDGE, MA · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source ↗

Atlas Venture Life Science Advisors, LLC reported 7 positions worth $881.3M as of June 30, 2026 (13F filed August 13, 2026). Largest holding: KYMR (37.1%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$881.3M

2026 Q2

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2026 Q2

Positions Changes Mix History BacktestPRO

7 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	KYMR	Kymera Therapeutics, Inc.	SH	$326.5M	37.05%	2,847,541	—	—
▸ 2	DYN	Dyne Therapeutics, Inc.	SH	$151.0M	17.14%	6,800,099	—	—
▸ 3	SION	Sionna Therapeutics, Inc.	SH	$131.8M	14.95%	2,995,602	—	—
▸ 4	KLRA	Kailera Therapeutics, Inc.	SH	$113.9M	12.93%	5,171,282	—	—
▸ 5	IRON	Disc Medicine, Inc.	SH	$110.7M	12.56%	1,513,875	—	—
▸ 6	QTTB	Q32 Bio, Inc.	SH	$34.6M	3.93%	2,717,106	—	—
▸ 7	KRRO	Korro Bio, Inc.	SH	$12.7M	1.44%	962,884	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Atlas Venture Life Science Advisors, LLC hold as of Q2 2026?

Atlas Venture Life Science Advisors, LLC reported 7 positions worth $881.3M in its Q2 2026 13F filing. Largest positions: KYMR (37.1%), DYN (17.1%), SION (15.0%), KLRA (12.9%) and IRON (12.6%).

What did Atlas Venture Life Science Advisors, LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Atlas Venture Life Science Advisors, LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.